Drug Approval | April 20, 2023
Zydus receives final approval from USFDA for Roflumilast Tablets, 250 mcg
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)